Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Literature DB >> 19454432

Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

R Stupp¹, F Roila.

Abstract

Entities: Disease

Mesh：

Year: 2009 PMID： 19454432 DOI： 10.1093/annonc/mdp151

Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976

Keyword Cloud
Cited

× No keyword cloud information.

46 in total

1. Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients.

Authors: Daniel Paech; Constantin Dreher; Sebastian Regnery; Jan-Eric Meissner; Steffen Goerke; Johannes Windschuh; Johanna Oberhollenzer; Miriam Schultheiss; Katerina Deike-Hofmann; Sebastian Bickelhaupt; Alexander Radbruch; Moritz Zaiss; Andreas Unterberg; Wolfgang Wick; Martin Bendszus; Peter Bachert; Mark E Ladd; Heinz-Peter Schlemmer
Journal: Eur Radiol Date: 2019-02-26 Impact factor: 5.315

2. Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Authors: Mary Lou Affronti; Sarah Woodring; Karen Allen; John Kirkpatrick; Katherine B Peters; James E Herndon; Frances McSherry; Patrick N Healy; Annick Desjardins; James J Vredenburgh; Henry S Friedman
Journal: Support Care Cancer Date: 2016-06-06 Impact factor: 3.603

Review 3. Cell-based immunotherapy against gliomas: from bench to bedside.

Authors: M Sarah S Bovenberg; M Hannah Degeling; Bakhos A Tannous
Journal: Mol Ther Date: 2013-05-07 Impact factor: 11.454

4. Proteome and Secretome Characterization of Glioblastoma-Derived Neural Stem Cells.

Authors: Satoshi Okawa; Sladjana Gagrica; Carla Blin; Christine Ender; Steven M Pollard; Jeroen Krijgsveld
Journal: Stem Cells Date: 2016-12-04 Impact factor: 6.277

Review 5. Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology.

Authors: Arnold B Etame; Roberto J Diaz; Christian A Smith; Todd G Mainprize; Kullervo Hynynen; James T Rutka
Journal: Neurosurg Focus Date: 2012-01 Impact factor: 4.047

10. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.

Authors: Pei Yang; Yongzhi Wang; Xiaoxia Peng; Gan You; Wei Zhang; Wei Yan; Zhaoshi Bao; Yinyan Wang; Xiaoguang Qiu; Tao Jiang
Journal: J Neurooncol Date: 2013-03-13 Impact factor: 4.130

Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

1. Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients.

2. Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Review 3. Cell-based immunotherapy against gliomas: from bench to bedside.

4. Proteome and Secretome Characterization of Glioblastoma-Derived Neural Stem Cells.

Review 5. Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology.

6. Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.

7. Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens.

8. Increased diffusion in the normal appearing white matter of brain tumor patients: is this just tumor infiltration?

Review 9. Overview of cellular immunotherapy for patients with glioblastoma.

10. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.